Cytek Biosciences Inc (CTKB)
Debt-to-equity ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 393,064 | 415,524 | 424,179 | 423,460 | 425,546 | 416,509 | 411,129 | 407,442 | 405,385 | 403,195 | -10,985 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $393,064K
= 0.00
The debt-to-equity ratio for Cytek Biosciences Inc has been consistently reported as 0.00 throughout the past 11 quarters, indicating that the company has not utilized any debt in its capital structure during this period. This suggests that Cytek Biosciences Inc has been primarily financed through equity, which may be seen as a positive sign of financial stability and a lower risk profile. It is important to note that a debt-to-equity ratio of 0.00 may not always be ideal, as some level of debt can be advantageous for a company's growth and tax benefits. However, the consistent lack of debt in Cytek Biosciences Inc's capital structure may reflect a deliberate strategic choice or the company's ability to fund its operations and investments using internal resources.
Peer comparison
Dec 31, 2023